All In Biotech

Drug Trial Radar · NCT04858334

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jun 22, 2021

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Sponsor type
NIH
First posted
Apr 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Conditions

  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Adenosquamous Carcinoma
  • Pancreatic Squamous Cell Carcinoma
  • Resectable Pancreatic Acinar Cell Carcinoma
  • Resectable Pancreatic Adenocarcinoma
  • Resectable Pancreatic Adenosquamous Carcinoma
  • Resectable Pancreatic Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • Computed TomographyProcedure

    Undergo CT or CT/MRI

  • Magnetic Resonance ImagingProcedure

    Undergo CT/MRI

  • OlaparibDrug

    Given PO

  • Placebo AdministrationDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in relapse-free survival (RFS)Time frame: From randomization to first documentation of disease recurrence (primary tumor relapse) or death, assessed from 22 months to 44 months

Locations

457 sites in 3 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Suspended

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Suspended

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Suspended

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Suspended

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Suspended

  • Providence Alaska Medical Center

    Anchorage, Alaska · Suspended

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska · Suspended

  • Kingman Regional Medical Center

    Kingman, Arizona · Recruiting

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Active not recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Suspended

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas · Suspended

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas · Suspended

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Active not recruiting

  • PCR Oncology

    Arroyo Grande, California · Suspended

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Recruiting

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Suspended

  • Palo Alto Medical Foundation-Fremont

    Fremont, California · Recruiting

  • Memorial Medical Center

    Modesto, California · Recruiting

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California · Suspended

  • Saint Joseph Hospital - Orange

    Orange, California · Recruiting

  • Sutter Roseville Medical Center

    Roseville, California · Recruiting

  • Sutter Medical Center Sacramento

    Sacramento, California · Recruiting

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California · Recruiting

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California · Active not recruiting

  • Mills Health Center

    San Mateo, California · Recruiting

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California · Recruiting

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California · Active not recruiting

  • Providence Medical Foundation - Santa Rosa

    Santa Rosa, California · Recruiting

  • Sutter Pacific Medical Foundation

    Santa Rosa, California · Recruiting

  • Providence Santa Rosa Memorial Hospital

    Santa Rosa, California · Suspended

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California · Recruiting

  • Northbay Cancer Center

    Vacaville, California · Recruiting

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado · Active not recruiting

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado · Active not recruiting

  • AdventHealth Porter

    Denver, Colorado · Suspended

  • CommonSpirit Cancer Center Mercy

    Durango, Colorado · Active not recruiting

  • Mercy Medical Center

    Durango, Colorado · Active not recruiting

  • CommonSpirit Saint Anthony Hospital Cancer Center

    Lakewood, Colorado · Active not recruiting

Showing 40 of 457 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.